Text

An Update, 10.12.14Malaysian Genomics Resource Centre Berhad

Our Journey So Far

2010, listing 2012-13, screening R&D 2014, screening rollout 2015, brighter future begins

© Copyright 2014. Malaysian Genomics Resource Centre Berhad. Private & Confidential.

Journey

Transformation

Reinvested in R&D to create new consumer segment - Screening Services Main stream of revenue from Contract Analytics Added additional streams of income: ‣ Screening Services ‣ Pathology Lab (JV with

Qualitas)

Growth

Focus on marketing. Established credentials and reputation. Tap into global industry: ‣ Outsource Contract

Analytics. ‣ More Contract Analytics

projects. Consumer focus: ‣ Pathology Lab. ‣ Screening Services, 40%

growth since 2013.

Malaysian Genomics Today

© Copyright 2014. Malaysian Genomics Resource Centre Berhad. Private & Confidential.

Proprietary Analytical Pipelines

Genetic & Genomic Expertise

Analytical Services

Plant Science

Human Health

Local, foreign institutions

Screening Services Pathology Lab Diagnostic Services

Local, foreign hospitals, clinics, doctors, and allied health specialists

Broadening Earnings Base

© Copyright 2014. Malaysian Genomics Resource Centre Berhad. Private & Confidential.

100%

Listing FY2010

100%

Analytical Services

15%5%

80%

Transformation FY2014

Analytical ServicesPathology LabScreening Services

5%20%

8%67%

Direction FY2017

Analytical ServicesPathology LabScreening ServicesDiagnostic Services

Growth Opportunities: Analytical Services

© Copyright 2014. Malaysian Genomics Resource Centre Berhad. Private & Confidential.

Global Market 1,2CAGR 21% (today – 2018), revenue US$8 – 12 billion 2018 est. Increase in outsourcing to Asia from US and EU.

1 BCC Research (2014). DNA Sequencing: Emerging Technologies and Applications. 2 Markets and Markets (2013). Bioinformatics Market By Sector, Segment & Application – Global Forecasts to 2017.

Key Drivers

means

more accessible sequencing

greater demand for sequencing and analysis

greater demand for sequencing and analysis

means

higher revenues for analysis due to limited supply

mean

more accessible sequencing

falling sequencing

costs

For Malaysian Genomics:We increased Analytical Services in healthcare (e.g. FELDA Wellness Project)

and in agriculture.

We started marketing beyond Malaysia for regional work.

We have seen positive transitions from Sales Pipeline to Order Book.

We are working to double the size of our Sales Pipeline before FY2016.

Growth Opportunities: Analytical Services

© Copyright 2014. Malaysian Genomics Resource Centre Berhad. Private & Confidential.

6.711.0

June 2014

25.0

12.0

December 2014

2.1 2.5

June 2013

Order Book (RM’m)

Sales Pipe. (RM’m)

Current Situationa) Clinipath;

has 11 branch labs serving 2,000 doctors; and operates in 7 medical centres.

b) Clinipath holds 6% share of Malaysia’s RM428 million private sector pathology market (2014 est.)

Growth Opportunities: Pathology Lab

© Copyright 2014. Malaysian Genomics Resource Centre Berhad. Private & Confidential.

Expansion PlanIncrease market share by; a) Increasing revenues per medical centre; b) Increasing from 7 to 10 medical centres over next 3

years; and c) Selling higher margin molecular tests.

6%

94%

2014 RM428m (est.)

10%

90%

2019 RM754m (est.)target

Current Situationa) Used for 70% of healthcare decisions made by doctors. b) Global market revenue US$80 billion (2020 est., Forbes). c) Fastest growing segment is molecular diagnostics.

Growth Opportunities: Diagnostic Services

© Copyright 2014. Malaysian Genomics Resource Centre Berhad. Private & Confidential.

Expansion Plana) Partner program with leading US and EU labs to bring best-

of-breed diagnostic tests to Malaysia. b) Looking beyond clinics to hospitals. c) Looking beyond Malaysia to region.

Text

Thank youMalaysian Genomics Resource Centre Berhad